# Coastlands Capital

> Coastlands Capital is a VC fund in San Francisco backing Biotechnology and Health Care. See 28 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: San Francisco, United States
- Total investments: 28
- Last investment: Jun 2026
- Lead investor: 25%
- Last updated: Aug 2026
- Website: https://coastlandscapital.com

Coastlands Capital is a VC fund in San Francisco focused on Biotechnology and Health Care. Coastlands Capital LP is an investment management firm based in San Francisco, California. The firm primarily invests in equity and equity-related securities that are publicly traded in both U.S. and non-U.S. markets. They employ a private equity approach to public market investing, focusing on identifying undervalued companies within growingsectors to generate returns for their clients.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 24 | 86% |
| Health Care | 16 | 57% |
| Therapeutics | 12 | 43% |
| Biopharma | 9 | 32% |
| Pharmaceutical | 9 | 32% |

12 industries tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 22 | 79% |
| China | 1 | 4% |
| France | 1 | 4% |
| Germany | 1 | 4% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Pyxis Oncology | Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer. The company has engaged in deep analyses of tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and of tumor cell signaling pathways within cold tumors, providing laboratories with development of novelantibody-based immunotherapies.It was founded in 2019 and is based in Boston, Massachusetts. | $50M | Post-IPO Equity | Jun 30, 2026 |  |
| Adial Pharmaceuticals | Adial Pharmaceuticals, LLC engages in the development of prescription medications for addiction and related disorders in the United States. The company's research pipeline includes AD04, a compound that completed Phase IIb study for the treatment of alcohol use disorders; and AD01, which completed Phase I clinical-stage for treating addictivebehaviors. | $32M | Post-IPO Equity | Jun 11, 2026 |  |
| Quince Therapeutics | Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currentlytesting several potential lead therapeutics in preclinical studies. | $115M | Post-IPO Equity | May 18, 2026 |  |
| Whitehawk Therapeutics | Aadi Bioscience was founded by Dr. Neil Desai, is a clinical-stage biopharmaceutical company developing the potentially best-in-class mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases. | $87.5M | Post-IPO Equity | May 13, 2026 |  |
| InflaRx | InflaRx develops new therapeutics in the field of acute and chronic inflammation and consists of a team of internationally recognized researchers and clinicians who have dedicated their careers to translate discoveries and expertise into new therapeutic concepts for clinical application.In April 2018, InflaRx conducted a USD 117 million totalgross proceeds follow-on transaction on the US Nasdaq global select market comprised of a primary component of USD 63 million investment into InflaRx as well as a secondary component of USD 54 million to existing first-day shareholders of InflaRx. InflaRx was founded in December 2017 and is headquartered in Jena, Germany. | $150M | Post-IPO Equity | May 06, 2026 |  |
| Sagimet Biosciences | Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways. The company has unique expertise in FASN biology and has created a pipeline of proprietary FASNinhibitors. | $175M | Post-IPO Equity | Apr 27, 2026 |  |
| Achieve Life Science | Achieve Life Science manufactures pharmaceutical products. The firm develops cytisine as a smoking cessation aid. | $180M | Post-IPO Equity | Apr 16, 2026 |  |
| ImageneBio | It is a leading biotech company focused on immunology-related therapeutic areas. | $30M | Post-IPO Equity | Apr 13, 2026 |  |
| OnKure Therapeutics | OnKure is a biotechnology company that commercializes a new cancer therapy based on novel, less toxic kinase inhibitor drugs. The company is engaged in the discovery and development of epigenetic therapies for the treatment of cancer that includes selective inhibitors of histone deacetylases. In pre-clinical models of both hematological and solidtumor cancers, their lead candidate, OKI-179, significantly and safely reduces the growth rate of tumors when dosed by itself or in combination with other targeted therapies.OnKure advances the HDAC3 selective inhibitor OKI-422 into pre-clinical toxicology studies. The company's drug candidates aim to treat patients by targeting malignant cells directly, by working in combination with other small molecule therapies and by priming the tumor microenvironment such that checkpoint inhibition is optimized. | $150M | Post-IPO Equity | Mar 27, 2026 |  |
| Ovid Therapeutics | Ovid is a pure play neurology company focused on rare and orphan diseases of the brain. They were founded in 2014 to leverage recent advances in science and medicine to find optimal therapies. They seek to identify and develop late stage, de-risked medicines with significant potential. Their rationale for developing these medicines is based onkey insights from their scientific founders and confirmed in discussions with leading experts in the field. Their products are protected by strong intellectual property. They apply the most efficient processes to bring safe and effective therapies to patients. They are based in New York City but have collaborators and are working with patients across the United States and the globe. | $60M | Post-IPO Equity | Mar 17, 2026 |  |

10 of 28 investments shown.

## Co-investors
- [Janus Henderson Investors](https://shizune.co/investors/profile/janus-henderson-investors) — VC Fund, 11 deals together
- [Vivo Capital](https://shizune.co/investors/profile/vivo-capital) — VC Fund, 10 deals together
- [ADAR1 Capital Management](https://shizune.co/investors/profile/adar1-capital-management) — VC Fund, 8 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 7 deals together
- [Trails Edge Capital Partners](https://shizune.co/investors/profile/trails-edge-capital-partners) — VC Fund, 7 deals together
- [Balyasny Asset Management](https://shizune.co/investors/profile/balyasny-asset-management) — VC Fund, 6 deals together

## Similar investors

### Similar stage
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund
- [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund

## FAQ

### What does Coastlands Capital invest in?

Coastlands Capital invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Post-IPO Equity stage. Most of the 28 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Coastlands Capital last invest?

The most recent investment recorded for Coastlands Capital closed in Jun 2026. Shizune tracks 28 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co